Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
IB
iBio, Inc. Common Stock
IBIO
Mkt Cap
$49.5M
Volume
304.13K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
IB
IBIO
IB
iBio, Inc. Common Stock
IBIO
News
·
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Mkt Cap
$50.3M
Volume
304.13K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
iBio, a clinical-stage biotechnology company, announced fiscal year 2026 results marking its transition to clinical development with initiation of Phase 1 trials for IBIO-600, a long-acting anti-myostatin antibody. The company advanced IBIO-610 into IND-enabling studies showing fat-selective weight loss potential and completed successful financings totaling $126 million, extending cash runway into fiscal 2028. R&D expenses increased to $19.6 million from $8.3 million year-over-year, while the company held $88 million in cash and investments.
GlobeNewswire Inc. · Aug 28, 2026
iBio Announces $26 Million Private Placement
iBio, Inc. (NASDAQ: IBIO) announced a private placement financing of approximately $26 million led by Frazier Life Sciences. The company will use proceeds to advance preclinical cardiometabolic programs including IBIO-610 and IBIO-600, extending cash runway into calendar 2028. The offering is expected to close on January 13, 2026.
GlobeNewswire Inc. · Jan 9, 2026
iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
iBio, an AI-driven biotechnology company, will present at the Guggenheim Healthcare Innovation Conference in Boston, discussing its development of precision antibody therapies for obesity and cardiometabolic diseases.
GlobeNewswire Inc. · Oct 23, 2025
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
iBio and AstralBio have developed a novel amylin receptor agonist antibody that significantly reduced acute food intake in a mouse model of obesity, comparable to a leading amylin peptide agonist. The findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases.
GlobeNewswire Inc. · Jun 24, 2025
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
iBio has in-licensed a potentially best-in-class long-acting anti-myostatin antibody from AstralBio and is launching a new program featuring a myostatin + activin A bispecific antibody designed to promote weight loss, prevent muscle loss and weight regain.
GlobeNewswire Inc. · Jan 2, 2025
Biopharmaceuticals Contract Manufacturing Industry Research 2024-2030: Biopharma Giants Increasingly Outsource to Streamline Drug Developments
The biopharmaceuticals contract manufacturing market is expected to grow at a steady CAGR due to the increasing prevalence of chronic diseases, growing R&D investments in biologics and biosimilars, and the rise in outsourcing by biopharma giants to streamline drug development.
GlobeNewswire Inc. · Oct 14, 2024
iBio to Participate in Upcoming Investor Conferences
iBio, Inc., an AI-driven innovator of precision antibody immunotherapies, announced that its CEO and CFO will participate in upcoming investor conferences, including the H.C. Wainwright 26th Annual Global Investment Conference and the 2024 Cantor Global Healthcare Conference.
GlobeNewswire Inc. · Sep 3, 2024
iBio Closes Sale of Manufacturing Facility in Texas
– The sale of the facility eliminates $13.2M of secured debt –
GlobeNewswire Inc. · Jun 3, 2024
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial results for the third quarter ended March 31, 2024 and provided a corporate update.
GlobeNewswire Inc. · May 13, 2024
Balancing Volatility With Stability When Trading Penny Stocks
Here's how to balance volatility with stability when profiting with penny stocks The post Balancing Volatility With Stability When Trading Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks · Mar 28, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
IB
IBIO
iBio, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
IBIO
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any IBIO yet.
Related Tickers
Earnings